Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends-Reference-Cited by-同舟云学术

Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends

Published:2009-08 Issue:8 Volume:31 Page:1619-1640
ISSN:0149-2918
Container-title:Clinical Therapeutics
language:en
Short-container-title:Clinical Therapeutics

Author:

Moreno-Aspitia Alvaro,Perez Edith A.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference105 articles.

1. Cancer statistics, 2008;Jemal;CA Cancer J Clin,2008

2. Residual risk of breast cancer recurrence 5 years after adjuvant therapy;Brewster;J Natl Cancer Inst,2008

3. Chemotherapy for metastatic breast cancer;Mayer;Hematol Oncol Clin North Am,2007

4. Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up;Kataja;Ann Oncol,2008

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ki-67 Change in Anthracyline-containing Neoadjuvant Chemotherapy Response in Breast Cancer;Current Medical Science;2024-02

2. Evaluation of the Cytotoxic Effects of the Novel Antineoplastic Agent 1,4,5-Oxathiazinane-4,4-dioxide on Triple Negative Breast Cancer Cells;Anticancer Research;2021-05

3. Multiple Topoisomerase I (TopoI), Topoisomerase II (TopoII) and Tyrosyl-DNA Phosphodiesterase (TDP) inhibitors in the development of anticancer drugs;European Journal of Pharmaceutical Sciences;2021-01

4. Beclin1 inhibition enhances paclitaxel‑mediated cytotoxicity in breast cancer in�vitro and in�vivo;International Journal of Molecular Medicine;2019-02-01

5. First report of eribulin in combination with pertuzumab and trastuzumab for advanced HER2-positive breast cancer;The Breast;2017-10